FDA Publishes Draft Guidance on Updating Abbreviated New Drug Application Labeling After Reference Listed Drug Withdrawal

Summary

The FDA has released a draft guidance outlining a process for updating labeling for abbreviated new drug applications (ANDAs) after the withdrawal of a new drug application (NDA) for a reference listed drug (RLD) due to reasons other than safety or effectiveness.